Aldose Reductase: a cause and a potential target for the treatment of diabetic complications

다국어 초록 (Multilingual Abstract)

Diabetes mellitus, a disorder of metabolism,results in the elevation of glucose level in the blood. In thishyperglycaemic condition, aldose reductase overexpressesand leads to further complications of diabetes through thepolyol pathway. Glucose metabolism-related disorders arethe accumulation of sorbitol, overproduction of NADH andfructose, reduction in NAD + , and excessive NADPH usage,leading to diabetic pathogenesis and its complications suchas retinopathy, neuropathy, and nephropathy. Accumulationof sorbitol results in the alteration of osmotic pressureand leads to osmotic stress. The overproduction of NADHcauses an increase in reactive oxygen species productionwhich leads to oxidative stress. The overproduction of fructosecauses cell death and non-alcoholic fatty liver disease.
Apart from these disorders, many other complications havealso been discussed in the literature. Therefore, the articleoverviews the aldose reductase as the causative agent and apotential target for the treatment of diabetic complications.
So, aldose reductase inhibitors have gained much importanceworldwide right now. Several inhibitors, like derivativesof carboxylic acid, spirohydantoin, phenolic derivatives,etc. could prevent diabetic complications are discussedin this article.

참고문헌 (Reference)

1 Liu F, "axifolin shows anticataractogenesis and attenuates diabetic retinopathy in STZ-diabetic rats via suppression of aldose reductase, oxidative stress, and MAPK signaling pathway" 20 : 599-608, 2020

2 Son NH, "ardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia" 7 (7): e46549-, 2012

3 Zhou X, "WJ-39, an aldose reductase inhibitor, ameliorates renal lesions in diabetic nephropathy by activating Nrf2 signaling" 30 : 2020-, 2020

4 Sanchez-Lozada LG, "Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats" 294 : 4272-4281, 2019

5 Singh Grewal A, "Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases" 16 : 120-162, 2016

6 Yadav UC, "Understanding the role of aldose reductase in ocular infl ammation" 10 : 540-549, 2010

7 Zhou LH, "Two Cu (II)-based coordination polymers: treatment activity on diabetic nephropathy via reducing aldose reductase activity and blood glucose concentration" 2021

8 padhyay RK, "Tulsi: a holy plant with high medicinal and therapeutic value" 11 (11): 1-12, 2017

9 Prnova MS, "Triglyceride-lowering eff ect of the aldose reductase inhibitor cemtirestat-another factor that may contribute to attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats" 393 : 651-661, 2020

10 Folli F, "The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro-and macrovascular complications: avenues for a mechanistic-based therapeutic approach" 7 : 313-324, 2011

11 Alwadani F, "The role and prevalence of polyol pathway and oxidative stress markers as risk factors for diabetic cataract in adult type-I diabetic and diabetic cataract saudi patients" 7 : 3-, 2016

12 Brownlee M, "The pathobiology of diabetic complications: a unifying mechanism" 54 (54): 1615-1162, 2005

13 He J, "The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in DB/DB mice through metabolic modulation" 40 : 86-97, 2019

14 Maccari R, "Targeting aldose reductase for the treatment of diabetes complications and infl ammatory diseases: new insights and future directions" 58 : 2047-2067, 2015

15 Manar G. Salem, "Synthesis and molecular modeling of novel non-sulfonylureas as hypoglycemic agents and selective ALR2 inhibitors" Elsevier BV 27 (27): 3383-3389, 2019

16 Jagdale AD, "Strong inhibition of the polyol pathway diverts glucose fl ux to protein glycation leading to rapid establishment of secondary complications in diabetes mellitus" 30 : 398-405, 2016

17 Wu J, "Sources and implications of NADH/NAD + redox imbalance in diabetes and its complications" 9 : 145-, 2016

18 Omotosho IO, "Sorbitol dehydrogenase activity in diabetes mellitus and cataract patients" 3 (3): 61-65, 2014

19 Huang Q, "Sorbinil, an aldose reductase inhibitor, in fi ghting against diabetic complications" 15 : 3-, 2019

20 Dubey K, "Role of aldose reductase in secondary diabetes complications" 9 (9): 20-20, 2018

21 Chang KC, "Role of aldose reductase in diabetes-induced retinal microglial activation" 30 : 46-52, 2019

22 Iyer S, "Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG" 2019

23 Sarikaya M, "Relationship between aldose reductase enzyme and the signaling pathway of protein kinase C in an in vitro diabetic retinopathy model" 98 : 243-251, 2020

24 Yan LJ, "Redox imbalance stress in diabetes mellitus: role of the polyol pathway" 1 : 7-13, 2018

25 Matsumoto T, "Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats" 07 : 231-237, 2008

26 Kubo ET, "Polyol pathwaydependent osmotic and oxidative stresses in aldose reductasemediated apoptosis in human lens epithelial cells: role of AOP2" 314 : 1050-1056, 2004

27 Mathebula SD, "Polyol pathway: a possible mechanism of diabetes complications in the eye" 74 : 5-, 2015

28 Hashimoto Y, "Polyol pathway and diabetic nephropathy revisited: early tubular cell changes and glomerulopathy in diabetic mice overexpressing human aldose reductase" 2 (2): 111-122, 2011

29 Wihandani DM, "Polymorphisms of aldose reductase (ALR2) regulatory gene are risk factors for diabetic retinopathy in type-2 diabetes mellitus patients in Bali, Indonesia" 12 : 281-, 2018

30 Li W, "Polymorphisms in sorbitol-aldose reductase (Polyol) pathway genes and their infl uence on risk of diabetic retinopathy among Han Chinese" 25 : 7073-, 2019

31 Vyas B, "Pharmacophore and docking-based hierarchical virtual screening for the designing of aldose reductase inhibitors: synthesis and biological evaluation" 25 : 609-626, 2016

32 Giacco F, "Oxidative stress and diabetic complications" 107 (107): 1058-1070, 2010

33 Hashim Z, "Osmotic stress-induced oxidative damage: possible mechanism of cataract formation in diabetes" 26 : 275-279, 2012

34 Hwang SH, "Novel aldose reductase inhibitory and antioxidant chlorogenic acid derivatives obtained by heat treatment of chlorogenic acid and amino acids" 266 : 449-457, 2018

35 Feldman EL, "New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain" 93 : 1296-1313, 2017

36 Satirapoj B, "Nephropathy in diabetes" 2013

37 Zhang X, "Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy" 215 : 113269-, 2021

38 Dewanjee S, "Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets" 833 : 472-523, 2018

39 Chawla A, "Microvascular and macrovascular complications in diabetes mellitus: distinct or continuum?" 20 : 546-, 016

40 Kota V. Ramana, "Mediation of aldose reductase in lipopolysaccharide-induced inflammatory signals in mouse peritoneal macrophages" Elsevier BV 36 (36): 115-122, 2006

41 Xu J, "Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy" 48 : 705-717, 2018

42 Cherku PD, "Inhibitory activity of leaf extract of Tinospora cordifolia and magnofl orine on aldose reductase for control of diabetes" 13 (13): 186-192, 2019

43 Dongare V, "Inhibition of aldose reductase and anticataract action of trans-anethole isolated from Foeniculum vulgare Mill. fruits" 132 : 385-390, 2012

44 Smeriglio A, "Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol" 127 : 101-108, 2018

45 Gurprit S, "Human aldose reductase unfolds through an intermediate" 2019

46 Yagihashi S, "Glucotoxic mechanisms and related therapeutic approaches" 127 : 121-149, 2016

47 Liu H, "Genetic defi ciency of aldose reductase counteracts the development of diabetic nephropathy in C57BL/6 mice" 5 : 1242-1251, 2011

48 Devi A, "Functional food and human health" Springer 555-574, 2018

49 Andleeb H, "Exploration of thioxothiazolidinone–sulfonate conjugates as a new class of aldehyde/aldose reductase inhibitors: a synthetic and computational investigation" 75 : 1-5, 2017

50 Jesús A. Rosas-Rodríguez, "Enzymes involved in osmolyte synthesis: How does oxidative stress affect osmoregulation in renal cells?" Elsevier BV 87 (87): 515-520, 2010

51 Decreased GF, "Endocrinology adult and pediatric: diabetes mellitus and obesity E-Book" 457-, 2013

52 Ota A, "Eff ects of long-term treatment with ranirestat, a potent aldose reductase inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii rats" 2013

53 hen H, "Eff ect of glutathione liposomes on diabetic nephropathy based on oxidative stress and polyol pathway mechanism" 9 : 1-9, 2020

54 American Diabetes Association, "Diagnosis and classifi cation of diabetes mellitus" 37 : 81-90, 2014

55 Ahsan H, "Diabetic retinopathy-biomolecules and multiple pathophysiologies" 9 : 51-54, 2015

56 Bayram EH, "Diabetic neuropathy and treatment strategy-new challenges and applications" 2016

57 Sucheta L, "Diabetic complication : cataract" 1 (1): 26-32, 2012

58 brosova IG, "Diabetic cataracts: mechanisms and management" 26 (26): 172-180, 2010

59 Pollreisz A, "Diabetic cataract-pathogenesis, epidemiology and treatment" 2010

60 Chatzopoulou M, "Development of aldose reductase inhibitors for the treatment of infl ammatory disorders" 8 (8): 1365-1380, 2013

61 Ji Y, "Designing of acyl sulphonamide based quinoxalinones as multifunctional aldose reductase inhibitors" 27 : 1658-1669, 2019

62 KumarPasala V, "Design, synthesis, and biological evaluation of selective hybrid coumarinthiazolidinedione aldose reductase-II inhibitors as potential antidiabetics" 114 : 104970-, 2021

63 Chen X, "Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold" 46 : 1536-1544, 2011

64 Kakar M, "Cross linkage between oxidative stresses in diabetic nephropathy : an updated review" 20 : 2875-2885, 2020

65 Volpe CMO, "Cellular death, reactive oxygen species (ROS) and diabetic complications" 9 (9): 1-9, 2018

66 Akileshwari C, "Biofl avonoid ellagic acid inhibits aldose reductase: implications for prevention of diabetic complications" 6 : 374-383, 2014

67 Benlarbi-Ben Khedher M, "Astaxanthin inhibits aldose reductase activity in Psammomysobesus, a model of type 2 diabetes and diabetic retinopathy" 7 : 3979-3985, 2019

68 Ayepola OR, "Antioxidant-antidiabetic agents and human health" IntechOpen 923-931, 2014

69 Lu Q, "Antidiabetic cataract eff ects of GbE, rutin and quercetin are mediated by the inhibition of oxidative stress and polyol pathway" 65 : 35-41, 2018

70 Kursun OE, "Alterations of aldose reductase activity by indole-3-carboxaldehyde derivatives" 30 : 13-24, 2021

71 Ramana KV, "Aldose reductase: new insights for an old enzyme" 2 : 103-114, 2011

72 Kota V. Ramana, "Aldose reductase: A novel therapeutic target for inflammatory pathologies" Elsevier BV 42 (42): 17-20, 2010

73 Tang W, "Aldose reductase, oxidative stress, and diabetic Mellitus" 3 : 87-, 2012

74 Kador PF, "Aldose reductase, ocular diabetic complications and the development of topical Kinostat®" 54 : 1-29, 2016

75 El-Kabbani O, "Aldose reductase structures: implications for mechanism and inhibition" 61 : 750-762, 2004

76 Quattrini L, "Aldose reductase inhibitors: 2013-present" 29 : 199-213, 2019

77 eeresham C, "Aldose reductase inhibitors of plant origin" 28 : 317-333, 2014

78 Schemmel KE, "Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review" 24 : 354-360, 2010

79 Zhu C, "Aldose reductase inhibitors as potential therapeutic drugs of diabetic complications. vol 2" 2013

80 Sekiguchi K, "Aldose reductase inhibitor ranirestat signifi cantly improves nerve conduction velocity in diabetic polyneuropathy: a randomized double-blind placebo-controlled study in Japan" 10 : 466-474, 2019

81 Snow A, "Aldose reductase expression as a risk factor for cataract" 234 : 247-253, 2015

82 Cheung AK, "Aldose reductase defi ciency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of DB/DB mice" 54 : 3119-3125, 2005

83 Baba SP, "Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE)" 191 : 357-363, 2011

84 Hashemi-Soteh MB, "Aldose reductase (AC) n gene polymorphism in Iranian patients with type 2 diabetic microangiopathy; a case–control study" 12 (12): 101-107, 2021

85 Huang SP, "Aldo-keto reductases in the eye" 2010

86 Wang Y, "Additive eff ect of aldose reductase Z-4 microsatellite polymorphism and glycaemic control on cataract development in type 2 diabetes" 28 (28): 147-151, 2014

87 Ferraro B, "Addition of the aldose reductase inhibitor benzofuroxane derivative BF-5m to prolonged and moderate exercise training enhanced protection of the rat heart from type-1 diabetes" 10 : 392-, 2019

88 Balestri F, "Acid derivatives of pyrazolo [1, 5-a] pyrimidine as waldoes reductase diff erential inhibitors" 25 : 1414-1418, 2018